Cartesian Therapeutics Inc 's ability to collect accounts receivable sequentially worsen to 2.52, indicating more challenging environment then in the second quarter 2026, but still, it is a far cry from any concerns. Cartesian Therapeutics Inc 's Accounts Receivable average collection period in the Sep 30 2026 quarter, has increased to 145 days, from 141 days, in the Jun 30 2026 quarter.

If we take a look into Healthcare sector 560 other companies have achieved higher receivables turnover ratio. While total ranking has deteriorated relative to the period ending Sep 30 2026 from 3823 to 3832.

What is Receivable Turnover Ratio?
What is Cartesian Therapeutics Inc Selling?

What is Receivable Turnover Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Accounts Receivables Turnover▼

None ▼

Accounts Receivables Turnover▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

RNAC Receivables Turnover Ratio	(Sep 30 2026) III. Quarter	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter
Y / Y Receivable Change	-92.8 %	-44.63 %	-85.21 %	27.87 %	-85.05 %
Y / Y Revenue Change	-	-	-92.91 %	-	16.8 %
Receivable Turnover Ratio (TTM)	2.52	2.58	2.9	2.83	1.18
RNAC's Total Ranking	# 3832	# 3823	# 3490	# 1637	#
Accounts Receivable average collection period days	145	142	126	129	311
Seq. Receivable Change	-73.47 %	-24.9 %	-76.59 %	54.43 %	103.95 %
Seq. Revenue Change	-	-	-91.76 %	109.51 %	51.68 %

Receivable Turnover Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 199
Healthcare Sector	# 561
Overall Market	# 3832

Receivable Turnover Ratio Statistics
High	Average	Low
0.77	0.24	0
(Jun 30 2022)		(Dec 31 2017)

News about Cartesian Therapeutics Inc Receivables Turnover Ratios

Cartesian Therapeutics Begins Phase 1 Trial of Descartes-15 A Next-Generation mRNA CAR-T Therapy Achieving Br...

In a significant leap forward in the field of cancer therapy, Cartesian Therapeutics, a pioneering biotechnology firm specializing in the development of next-generation mRNA-based cell therapies, has announced that the first patient has been dosed in its first-in-human Phase 1 clinical trial evaluating Descartes-15, its novel mRNA CAR-T cell therapy. This milestone marks a crucial step in the company s mission to innovate cancer treatments that are more effective and safer for patients suffering from hematologic malignancies. Understanding CAR-T Cell Therapy Chimeric Antigen Receptor T-cell (CAR-T) therapy has transformed the landscape of oncology, providing a personalized approach that harnesses the body’s immune system to fight cancer. Traditional CAR-T therapies have already made significant impacts in treating certain blood cancers, but they are often accompanied by adverse effects and limitations in efficacy.

RNAC Company Profile • Back to RNAC Efficiency Comparisons • Compare RNAC Receivables Turnover Ratio to its Competitors

Financial Statements
Cartesian Therapeutics Inc 's Accounts Receivable	$ 0 Millions	Visit RNAC's Balance sheet
Cartesian Therapeutics Inc 's Sales TTM	$ 1 Millions	Visit RNAC's Income Statement
Sources of RNAC's Revenues		Visit RNAC's Sales by Geography

Other Accounts Receivable Turnover Ratios
Major Pharmaceutical Preparations Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
RNAC's Receivable Turnover Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
RNAC's Growth Rates	RNAC's Roa	RNAC's Inventory Turnover Ratio	RNAC's Dividend Comparisons
RNAC's Profitability Ratios	RNAC's Roi	RNAC's Asset Turnover Ratio	RNAC's Dividend Growth
RNAC's Valuation Ratios	RNAC's Roe	RNAC's Financial Strength Ratios	RNAC's Dividend Payout Ratio

Companies with similar Receivables Turnover Ratio for the quarter ending Sep 30 2026, within Healthcare Sector	Receivable Turnover Ratio	Revenues for 12 Months ending Sep 30 2026	Receivable at quarter ending Sep 30 2026
Kiniksa Pharmaceuticals International Plc	40.65	$ 945.963 Millions	$ 23.272 Millions
Innovage Holding Corp	34.59	$ 1,018.359 Millions	$ 29.443 Millions
Fortrea Holdings Inc	29.58	$ 2,666.700 Millions	$ 90.150 Millions
Sonida Senior Living Inc	27.65	$ 638.130 Millions	$ 23.076 Millions
Wave Life Sciences Ltd	24.65	$ 87.296 Millions	$ 3.541 Millions
Lenz Therapeutics Inc	24.39	$ 12.359 Millions	$ 0.507 Millions
Arvinas Inc	20.06	$ 275.300 Millions	$ 13.725 Millions
U S Physical Therapy Inc	18.16	$ 837.629 Millions	$ 46.137 Millions
Alpha Pro Tech Ltd	17.54	$ 64.940 Millions	$ 3.702 Millions
Biogen Inc	15.19	$ 10,297.300 Millions	$ 677.900 Millions
Lifestance Health Group Inc	14.89	$ 1,676.889 Millions	$ 112.631 Millions
Amneal Pharmaceuticals Inc	14.24	$ 3,196.184 Millions	$ 224.488 Millions
Corcept Therapeutics Inc	13.44	$ 963.647 Millions	$ 71.710 Millions
Precipio inc	13.38	$ 27.762 Millions	$ 2.075 Millions
Chemed Corporation	12.65	$ 2,661.041 Millions	$ 210.387 Millions
Caredx Inc	11.75	$ 497.396 Millions	$ 42.330 Millions
Teladoc Health Inc	11.50	$ 2,468.143 Millions	$ 214.604 Millions
Biodesix Inc	11.45	$ 105.212 Millions	$ 9.192 Millions
Gossamer Bio Inc	11.37	$ 78.423 Millions	$ 6.896 Millions
Icu Medical Inc	11.32	$ 2,183.556 Millions	$ 192.845 Millions
Mannkind Corporation	10.97	$ 413.370 Millions	$ 37.686 Millions
Lensar Inc	10.64	$ 60.079 Millions	$ 5.645 Millions
Iqvia Holdings Inc	10.43	$ 17,311.000 Millions	$ 1,659.500 Millions
Voyager Therapeutics Inc	9.84	$ 25.108 Millions	$ 2.551 Millions
Myomo Inc	9.66	$ 47.775 Millions	$ 4.947 Millions
Encompass Health Corporation	9.41	$ 6,338.100 Millions	$ 673.625 Millions
Bausch Health Companies Inc	9.15	$ 11,113.000 Millions	$ 1,215.000 Millions
Co diagnostics Inc	9.12	$ 0.859 Millions	$ 0.094 Millions
Pacs Group Inc	8.88	$ 5,705.049 Millions	$ 642.729 Millions
Lexicon Pharmaceuticals Inc	8.77	$ 38.537 Millions	$ 4.396 Millions

Date modified: 2026-11-06T09:20:02+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.